Waystar (WAY) Shares Rise +8% on Solid Q2 Results and Upgraded Outlook
Key Takeaways
- Waystar shares have gained approximately 8% over the last 30 days, rebounding from a mid-July dip and climbing above the $24 level following strong second-quarter results.
- Q2 2026 revenue reached $320 million, up 18% year-over-year, while adjusted EBITDA of $137 million exceeded Wall Street expectations.
- The company raised its full-year 2026 revenue guidance to a range of $1.276 billion to $1.294 billion, with adjusted EBITDA projected between $535 million and $545 million.
- AI-powered solutions now drive roughly 40% of new bookings, reinforcing Waystar's strategic positioning in the healthcare revenue cycle automation space.
- The Iodine acquisition continues to generate cross-selling momentum, with over $6 million in bookings from existing Waystar clients adopting Iodine capabilities.
- Analyst consensus remains broadly positive, with a Moderate Buy rating and an average price target of approximately $35, implying significant potential upside from current levels.
Current Market Snapshot
Waystar Holding Corp. (NASDAQ: WAY) traded near $24.23 as of early August 2026, reflecting a steady recovery from the mid-$20 level earlier in the summer. The stock has navigated a volatile 2026, touching a 52-week low of $17.26 earlier in the year amid broader market fears around AI disruption in healthcare IT, while its 52-week high stands at $41.47. Over the last 30 days, shares have climbed approximately 8%, supported by an encouraging second-quarter earnings release, upwardly revised full-year guidance, and a new $200 million stock repurchase authorization. Institutional interest remains robust, with major holders including Vanguard, Advent International, and William Blair maintaining or increasing their positions. The 50-day moving average sits near $21.20, while the 200-day moving average hovers around $22.96, placing the stock comfortably above both medium- and long-term trend indicators. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.
Waystar (WAY) Business Overview and Competitive Position
Waystar provides a mission-critical, cloud-based platform that simplifies healthcare payments for over 30,000 clients, representing more than one million distinct providers across the United States. The company's enterprise-grade software spans the entire revenue cycle—from pre-service financial clearance and eligibility verification through claims submission, denial management, and payer remittance reconciliation. Annually, Waystar processes over 7.5 billion healthcare payment transactions, including more than $2.4 trillion in gross claims, touching approximately 60% of U.S. patients. Its client roster includes 16 of the 20 institutions on the U.S. News Best Hospitals list. Waystar's competitive moat rests on deep workflow integration, proprietary data assets, and an expanding suite of AI-powered automation tools that create meaningful switching costs. The acquisition of Iodine, a clinical documentation improvement specialist, has strengthened Waystar's mid-cycle capabilities and positioned the company to pursue a vision of an autonomous revenue cycle platform that reduces denials, accelerates reimbursement, and lowers the cost to collect for healthcare providers.
Recent Developments Driving WAY
Waystar reported second-quarter 2026 results on July 29 that surpassed consensus estimates, with revenue climbing 18% year-over-year to $320 million and adjusted earnings per share of $0.43 versus the $0.40 analysts expected. Subscription revenue—now representing 55% of total revenue—grew 34% year-over-year, while organic subscription growth reached 12%. The company also raised its full-year 2026 guidance, lifting the revenue midpoint to approximately $1.285 billion and the adjusted EBITDA midpoint to roughly $540 million. Shortly after earnings, on August 7, Barclays reiterated its Overweight rating, while Needham & Company reaffirmed a Buy rating with a $33 price target. Earlier in the quarter, Waystar announced a $200 million share repurchase authorization, signaling management's confidence in long-term shareholder value. On the product front, the company's next-generation AI anomaly detection solution gained traction, with over a dozen client commitments and early adopters recovering an estimated $3 million in incremental revenue per 10,000 admissions. External recognition also bolstered sentiment: Waystar was named to the Time 100 Most Influential Companies list and received the Time Impact in AI award, validating its strategy at the intersection of healthcare payments and artificial intelligence.
2026 Outlook and What Investors Should Watch
Looking ahead, Waystar's trajectory will be shaped by several key factors. The ongoing integration of Iodine and the expansion of AI-powered solutions represent the most significant growth catalysts; management has articulated a long-term vision of building an autonomous revenue cycle platform, and execution against that roadmap will be closely monitored. Bookings momentum—particularly among large health systems with $1 million-plus annual contract values—remains robust, though longer implementation timelines mean revenue recognition from these deals may be gradual. Macroeconomic variables, including potential changes to Medicaid coverage and shifts in the uninsured population, could influence transaction volumes and provider demand for Waystar's software. Additionally, the competitive landscape in AI-driven healthcare IT continues to evolve rapidly, and investors should watch for further analyst rating changes, institutional positioning updates, and any signals around the pace of client adoption for the company's newer AI SKUs. Waystar's ability to sustain organic subscription growth in the 10-12% range while maintaining adjusted EBITDA margins above 40% will be critical metrics in assessing the durability of its current momentum. From what I see, this is important because sustained execution here could support further upside.
Exploring AI Trading Strategies with Tickeron
For investors seeking data-driven approaches to navigate markets like the one Waystar operates in, I often review Tickeron’s Trending AI Robots page. It offers a curated selection of top-performing AI trading bots that collectively trade thousands of tickers across various strategies, timeframes, and performance metrics. The trending section highlights only those bots currently demonstrating standout results, helping align automated strategies with evolving conditions. Bots vary in approach, from short-term momentum to longer-term trend following, giving flexibility to match personal objectives. This serves as a useful starting point when integrating AI insights into research.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
WAY in upward trend: price expected to rise as it breaks its lower Bollinger Band on September 10, 2026
WAY may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options. In 16 of 19 cases where WAY's price broke its lower Bollinger Band, its price rose further in the following month. The odds of a continued upward trend are 84%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The Moving Average Convergence Divergence (MACD) for WAY just turned positive on September 16, 2026. Looking at past instances where WAY's MACD turned positive, the stock continued to rise in 17 of 22 cases over the following month. The odds of a continued upward trend are 77%.
WAY moved above its 50-day moving average on September 14, 2026 date and that indicates a change from a downward trend to an upward trend.
Following a +13.63% 3-day Advance, the price is estimated to grow further. Considering data from situations where WAY advanced for three days, in 107 of 135 cases, the price rose further within the following month. The odds of a continued upward trend are 79%.
The Aroon Indicator entered an Uptrend today. In 61 of 73 cases where WAY Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 84%.
Bearish Trend Analysis
The Stochastic Oscillator has been in the overbought zone for 2 days. Expect a price pull-back in the near future.
The Momentum Indicator moved below the 0 level on September 18, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on WAY as a result. In 26 of 41 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 63%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where WAY declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 78%.
Fundamental Analysis (Ratings)
The Tickeron Price Growth Rating for this company is 45 (best 1 - 100 worst), indicating steady price growth. WAY’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Valuation Rating of 68 (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (1.234) is normal, around the industry mean (7.474). P/E Ratio (36.657) is within average values for comparable stocks, (46.724). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (2.134). Dividend Yield (0.000) settles around the average of (0.010) among similar stocks. P/S Ratio (4.228) is also within normal values, averaging (6.065).
The Tickeron SMR rating for this company is 86 (best 1 - 100 worst), indicating slightly better than average sales and a considerably profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron PE Growth Rating for this company is 90 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. WAY’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 98, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
Industry ServicestotheHealthIndustry
Advertisement